Publication: Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy
This research article, published in the Journal of Comparative Effectiveness Research, provides results of meta-analyses comparing the efficacy of different corticosteroids in the management of nonsense mutation Duchenne muscular dystrophy (nmDMD)
Learn more about the clinical trials included in these meta-analyses, including information about the study populations
Review the results assessing the efficacy of both treatments in slowing disease progression in patients with nmDMD, including change in 6-minute walk distance and timed function tests, including 10-minute walk/run, 4-stair climb, and 4-stair descend
Read more about the common treatment-emergent adverse events for different corticosteroids
Once registered, you will be able to view the abstract and be provided the DOI and PubMed links for this publication.
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at email@example.com.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. PTC Therapeutics is the Marketing Authorization Holder for deflazacort in the US only. Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The US Prescribing Information for deflazacort is available here. Please refer to your local country guidance for more information.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2200118 | May 2022
Sign in or register to access exclusive content on this site